305 related articles for article (PubMed ID: 32564483)
21. The role of the microbiome in liver disease.
Schöler D; Schnabl B
Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
[TBL] [Abstract][Full Text] [Related]
22. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond.
Ohtani N; Kamiya T; Kawada N
Hepatol Commun; 2023 Sep; 7(9):. PubMed ID: 37639702
[TBL] [Abstract][Full Text] [Related]
23. Research progress of gut microbiota in hepatocellular carcinoma.
Li K; Liu J; Qin X
J Clin Lab Anal; 2022 Jul; 36(7):e24512. PubMed ID: 35719048
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory Milieu Related to Dysbiotic Gut Microbiota Promotes Tumorigenesis of Hepatocellular Carcinoma.
Huang C; Mei S; Zhang X; Tian X
J Clin Gastroenterol; 2023 Sep; 57(8):782-788. PubMed ID: 37406184
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.
Deng T; Li J; He B; Chen B; Liu F; Chen Z; Zheng J; Shi Z; Zhang T; Deng L; Yu H; Yang J; Wu L; Shan Y; Yu Z; Chen X; Wang Y; Chen G
Hepatol Int; 2022 Feb; 16(1):99-111. PubMed ID: 35064546
[TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
Boursier J; Diehl AM
Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
[TBL] [Abstract][Full Text] [Related]
27. The Microbiome and Liver Cancer.
Myojin Y; Greten TF
Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.
Jia W; Rajani C; Xu H; Zheng X
Protein Cell; 2021 May; 12(5):374-393. PubMed ID: 32797354
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
[TBL] [Abstract][Full Text] [Related]
30. The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection.
Yang R; Xu Y; Dai Z; Lin X; Wang H
J Immunol Res; 2018; 2018():2361963. PubMed ID: 30148173
[TBL] [Abstract][Full Text] [Related]
31. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.
Grąt M; Wronka KM; Krasnodębski M; Masior Ł; Lewandowski Z; Kosińska I; Grąt K; Stypułkowski J; Rejowski S; Wasilewicz M; Gałęcka M; Szachta P; Krawczyk M
Transplant Proc; 2016 Jun; 48(5):1687-91. PubMed ID: 27496472
[TBL] [Abstract][Full Text] [Related]
32. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
33. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE
Loo TM; Kamachi F; Watanabe Y; Yoshimoto S; Kanda H; Arai Y; Nakajima-Takagi Y; Iwama A; Koga T; Sugimoto Y; Ozawa T; Nakamura M; Kumagai M; Watashi K; Taketo MM; Aoki T; Narumiya S; Oshima M; Arita M; Hara E; Ohtani N
Cancer Discov; 2017 May; 7(5):522-538. PubMed ID: 28202625
[TBL] [Abstract][Full Text] [Related]
34. Microbiota, NASH, HCC and the potential role of probiotics.
Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
[TBL] [Abstract][Full Text] [Related]
35.
Ma H; Yang L; Liang Y; Liu F; Hu J; Zhang R; Li Y; Yuan L; Feng F
Gut Microbes; 2024; 16(1):2297846. PubMed ID: 38270111
[TBL] [Abstract][Full Text] [Related]
36. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.
Wan MLY; El-Nezami H
Hepatobiliary Surg Nutr; 2018 Feb; 7(1):11-20. PubMed ID: 29531939
[TBL] [Abstract][Full Text] [Related]
37. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.
Piñero F; Vazquez M; Baré P; Rohr C; Mendizabal M; Sciara M; Alonso C; Fay F; Silva M
Ann Hepatol; 2019; 18(3):480-487. PubMed ID: 31023615
[TBL] [Abstract][Full Text] [Related]
38. Zn(II)-curcumin solid dispersion impairs hepatocellular carcinoma growth and enhances chemotherapy by modulating gut microbiota-mediated zinc homeostasis.
Wu R; Mei X; Ye Y; Xue T; Wang J; Sun W; Lin C; Xue R; Zhang J; Xu D
Pharmacol Res; 2019 Dec; 150():104454. PubMed ID: 31526871
[TBL] [Abstract][Full Text] [Related]
39. Distinctly altered gut microbiota in the progression of liver disease.
Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.
Russo E; Fiorindi C; Giudici F; Amedei A
World J Hepatol; 2022 Feb; 14(2):372-385. PubMed ID: 35317185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
